IDEXX Laboratories
IDXX
#449
Rank
NZ$98.09 B
Marketcap
NZ$1,245
Share price
-1.35%
Change (1 day)
-1.26%
Change (1 year)

P/E ratio for IDEXX Laboratories (IDXX)

P/E ratio as of November 2026 (TTM): 48.6

According to IDEXX Laboratories's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 48.6197. At the end of 2022 the company had a P/E ratio of 50.2.

P/E ratio history for IDEXX Laboratories from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202250.2-33.31%
202175.32.64%
202073.439.42%
201952.622.55%
201843.0-17.58%
201752.110.24%
201647.334.23%
201535.2-14.47%
201441.236.68%
201330.15.21%
201228.66.07%
201127.0-4.81%
201028.410.4%
200925.738.17%
200818.6-51.47%
200738.344%
200626.6-10.9%
200529.925.29%
200423.8-13.98%
200327.713.04%
200224.5-2.83%
200125.2

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Abbott Laboratories
ABT
40.7-16.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
37.8-22.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Henry Schein
HSIC
25.8-46.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Meridian Bioscience
VIVO.defunct
35.0-27.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Neogen
NEOG
-47.0-196.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Heska Corporation
HSKA
-62.2-227.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Petco
WOOF
26.9-44.75%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.